Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel is the cornerstone of treatment for patients undergoing angioplasty with coronary stent implantation. However, some of these patients, despite the use of aspirin and clopidogrel, are not effectively anti-aggregated, a phenomenon known as resistance to antiplatelet agents. Its prevalence, as well as the conditions associated with it, is unknown in our country.
Objective: To determine the prevalence of clopidogrel resistance, as well as variables associated with it.
Methods: Patients admitted for elective angioplasty in chronic use of ASA and clopidogrel between January 2007 and January 2010 were studied. One hour after the procedure, platelet aggregation was measured using optical aggregometry with adenosine diphosphate 5 mmoles / l as agonist. At that moment, in a cross-sectional cohort, we determined the prevalence of clopidogrel resistance, defined as the value of platelet aggregation ≥ 43% and a logistic regression model to the variables associated with it.
Results: A total of 205 patients were analyzed (66.4 ± 11 years, 61.5% males). The prevalence of clopidogrel resistance was 38.5% (95% CI: 31.9 - 45.2%). Blood glucose (OR = 1.014; 95%CI: 1.004 - 1.023), previous myocardial infarction (OR = 2.320; 95%CI: 1.1103 - 4.892) and therapeutic response to ASA (OR = 1.057; 95%CI: 1.017 - 1.099) were the variables independently associated with clopidogrel resistance.
Conclusion: The prevalence of clopidogrel resistance was high. Glycemia, acute myocardial infarction and response to ASA were variables associated with it. A better understanding of this phenomenon is necessary considering the new antiplatelet aggregant agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0066-782x2012005000107 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.
J Am Coll Cardiol
September 2025
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Background: Genetic variants in cardiomyopathy genes are associated with risk of atrial fibrillation (AF), although data on clinical outcomes for AF patients with such variants remain sparse.
Objectives: We aimed to study the prognostic implication of rare cardiomyopathy-associated pathogenic variants (CMP-PLP) in AF patients from large, well-phenotyped clinical trials.
Methods: CMP-PLP carriers were identified using exome sequencing in 5 multinational trials from the Thrombolysis in Myocardial Infarction study group (ENGAGE AF, FOURIER, SAVOR, PEGASUS, and DECLARE), with replication in the EAST-AFNET-4 trial.
Characteristics of intracerebral hemorrhage associated with dual antiplatelet treatment.
J Neurol
August 2025
Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
Background: Antiplatelet treatment is associated with hematoma expansion (HE) and poor outcome in intracerebral hemorrhage (ICH). We aimed to describe the characteristics of ICH associated with dual antiplatelet treatment (DAPT), compared with single (SAPT) and no antiplatelet treatment (NAPT).
Methods: A retrospective analysis of ICH patients admitted at nine academic stroke centers in Italy, Germany, and China was conducted.
Drug response testing for elective carotid artery stenting: Prevalence of non-response to aspirin and clopidogrel and influence on post-interventional occurrence of cerebral ischemia.
Neuroradiol J
August 2025
Department of Neuroradiology, University Hospital RWTH Aachen, Aachen, Germany.
BackgroundThe patient-associated prevalence of Clopidogrel (CPG)-and Aspirin (ASS)-nonresponse is not well understood and varies depending on the patient population. The influence of responder status for platelet inhibition in patients eligible for carotid artery stenting (CAS) on post-interventional cerebral ischemia is unknown.MethodsWe conducted a retrospective, mono-center analysis of all patients with response-test undergoing elective CAS between 2010 and 2024 and available MRI before and after CAS.
View Article and Find Full Text PDFPrescription Drugs in Pregnancy and Congenital Malformations: A Population-Based Safety Screening Study.
Pharmacoepidemiol Drug Saf
September 2025
Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
Background: Counseling women who are either pregnant or contemplating pregnancy on their use of prescribed drugs remains a major clinical challenge. Since the thalidomide tragedy in the 1960s, the use of drugs during pregnancy has been subject to widespread concern due to the potential for unwanted effects on the unborn child, notably major congenital malformations.
Objective: To examine the risk of major congenital malformations following first trimester exposure to all marketed prescription drugs in Denmark.
Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated Participants.
Clin Pharmacol Ther
August 2025
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Black individuals undergoing percutaneous coronary intervention (PCI) experience higher rates of major adverse cardiovascular events (MACE) than non-Black individuals. This study assessed the racial differences in platelet reactivity and clinical outcomes among clopidogrel-treated participants. Two cohorts were analyzed.
View Article and Find Full Text PDF